Skip to main content

Spyre Therapeutics

Spyre Therapeutics Inc is an American clinical-stage biotechnology company focused on the discovery, development, and commercialization of next-generation antibody therapeutics for inflammatory bowel disease (IBD) and other immune-mediated gastrointestinal disorders. The company utilizes proprietary antibody engineering and protein design platforms to create therapeutic candidates targeting validated biological pathways with enhanced potency, half-life extension, and improved dosing profiles. Its core business activities encompass preclinical immunological research, clinical trial advancement, biopharmaceutical drug design, and regulatory compliance. As a clinical-stage biotechnology enterprise, the company generates minimal commercial revenue and finances its drug research pipeline through public equity offerings and venture capital financing. Spyre Therapeutics holds a pioneering position in advanced immunology and IBD drug discovery. The company is headquartered in Waltham, Massachusetts, United States, and its common stock trades on the Nasdaq Global Select Market.

8 of the funds FundTelligence covers report a position in Spyre Therapeutics.

Legal name
Spyre Therapeutics Inc
Sector
Health Care
Country
United States
Funds holding it
8

Funds holding Spyre Therapeutics

Loading...